Sina Naghshi

Sina Naghshi

Auto-generated profile, based on publicly available information

Sina Naghshi

Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2022 in Public Health Nutrition
Verified
Journal Article
Open access
PDF file
HTHelda Tutunchi
Helda Tutunchi
SNSina Naghshi
Sina Naghshi
MNMohammad Naemi
Mohammad Naemi
FNFatemeh Naeini
Fatemeh Naeini
AEAhmad Esmaillzadeh
Ahmad Esmaillzadeh
Objectives: To quantify the dose–response relation between yogurt consumption and risk of mortality from all causes, CVD and cancer.Design: Systematic review and meta-analysis.Setting: We conducted a comprehensive search of PubMed/Medline, ISI Web of Science and Scopus databases through August 2022 for cohort studies reporting the association of yogurt consumption with mortality from all causes, CVD and cancer. Summary relative risks (RR) and 95 % CI were calculated with a random-effects model.Participants: Seventeen cohort studies (eighteen publications) of 896 871 participants with 75 791 deaths (14 623 from CVD and 20 554 from cancer).Results: High intake of yogurt compared with low intake was significantly associated with a lower risk of deaths from all causes (pooled RR 0·93; 95 % CI: 0·89, 0·98, I2 = 47·3 %, n 12 studies) and CVD (0·89; 95 % CI: 0·81, 0·98, I2 = 33·2 %, n 11), but not with cancer (0·96; 95 % CI: 0·89, 1·03, I2 = 26·5 %, n 12). Each additional serving of yogurt consumption per d was significantly associated with a reduced risk of all-cause (0·93; 95 % CI: 0·86, 0·99, I2 = 63·3 %, n 11) and CVD mortality (0·86; 95 % CI: 0·77, 0·99, I2 = 36·6 %, n 10). There was evidence of non-linearity between yogurt consumption and risk of all-cause and CVD mortality, and there was no further reduction in risk above 0·5 serving/d.Conclusion: Summarising earlier cohort studies, we found an inverse association between yogurt consumption and risk of all-cause and CVD mortality; however, there was no significant association between yogurt consumption and risk of cancer mortality.

3 June 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
SPSanaz Pourreza
Sanaz Pourreza
ZKZeinab Khademi
Zeinab Khademi
AMAtieh Mirzababaei
Atieh Mirzababaei
MYMir Saeed Yekaninejad
Mir Saeed Yekaninejad
KSKhosro Sadeghniiat‐Haghighi
Khosro Sadeghniiat‐Haghighi
KMKhadijeh Mirzaei
Khadijeh Mirzaei

8 March 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
HTHelda Tutunchi
Helda Tutunchi
FNFatemeh Naeini
Fatemeh Naeini
MEMehrangiz Ebrahimi‐Mameghani
Mehrangiz Ebrahimi‐Mameghani
MMMajid Mobasseri
Majid Mobasseri
SNSina Naghshi
Sina Naghshi
AOAlireza Ostadrahimi
Alireza Ostadrahimi

1 January 2022 in International Journal Of Clinical Practice
Verified
Journal Article
Open access
PDF file
MMMasoume Mansouri
Masoume Mansouri
SNSina Naghshi
Sina Naghshi
MPMahbobeh Parsaeian
Mahbobeh Parsaeian
SSSadaf G. Sepanlou
Sadaf G. Sepanlou
HPHossein Poustchi
Hossein Poustchi
APAkram Pourshams
Akram Pourshams
Background. Epidemiological studies have reported inconsistent associations between opium use and cancer risk. We therefore conducted a systematic review and meta‐analysis to investigate the relationship between opium use and cancer risk. Methods. We searched PubMed, Scopus, ISI Web of Knowledge, and Google Scholar until February 2021 and references of retrieved relevant articles for observational studies that reported the risk of cancer in relation to opium use. Random‐effects models were used to calculate pooled effect sizes (ESs) as well as 95% confidence intervals (CIs) for the association between opium use and cancer risk by considering opium doses and types, duration of consumption, and routes of opium use. Results. In total, 21 observational articles, with a total sample size of 64,412 individuals and 6,658 cases of cancer, were included in this systematic review and meta‐analysis. Ever opium users, compared with never opium users, had 3.53 times greater risk of overall cancer (pooled ES: 3.53, 95% CI: 2.60–4.79, P ≤ 0.01). This positive association was also seen for some individual types of cancers except for esophageal and colon cancers. Also, we found that higher opium doses and higher duration of consumption were associated with an increased risk of overall and individual types of cancer. However, the associations between opium doses and the risk of head and neck and larynx cancers were not significant. In terms of the routes of opium use, both opium ingestion and smoking were positively associated with the risk of cancer. Regarding opium types, we found that using teriak, but not shireh, could increase the risk of cancer. Conclusions. Our findings showed that opium use, particularly in the form of teriak, is a risk factor for cancer.

6 May 2022 in Frontiers in Nutrition
Verified
Journal Article
Open access
FGFatemeh Gholami
Fatemeh Gholami
SNSina Naghshi
Sina Naghshi
MSMahsa Samadi
Mahsa Samadi
NRNiloufar Rasaei
Niloufar Rasaei
KMKhadijeh Mirzaei
Khadijeh Mirzaei
Findings on the association between dietary acid load (DAL) and bone health are conflicting. This study aimed to summarize available studies on the association between DAL and risk of fractures or bone mineral density (BMD) in adults. Online databases including PubMed, Scopus, and Embase were searched for relevant studies published up to June 2021, using pertinent keywords. We identified observational studies (cohort, case-control, and cross-sectional) investigating the association between DAL and risk of fractures or BMD, then selected studies following these reported criteria: RRs with corresponding 95% CIs for the relationship between DAL and fracture risk; correlation coefficients for the association between DAL and BMD; and mean ± SD of BMD values across the categories of DAL. Overall, 17 studies with 80545 individuals were included. There was no significant relationship between the PRAL and fracture risk (Pooled RR: 1.18; 95% confidence interval 0.98 to 1.41, I2 = 60.6%). Moreover, a similar association was observed between the NEAP and fracture risk (Pooled RR: 1.41, 95% CI: 0.79 to 2.52, I2 = 54.1%). The results of five studies from four publications revealed no significant association between dietary PRAL score and femoral and spinal BMD (WMD femoral = −0.01, 95% confidence interval: −0.02 to 0.01, I2 = 76.5%; WMD spinal = −0.01, 95% CI: −0.03 to 0.01, I2 = 56.7%). However, being in the highest category of NEAP was significantly associated with a lower femoral and spinal BMD (WMD femoral = −0.01, 95% CI: −0.02 to −0.00, I2 = 82.1%; WMD spinal = −0.02, 95% CI: −0.03 to −0.01, I2 = 93%). It was showed that adopting diets high in acidity was not associated with risk of fractures. We also found a significant negative relationship between NEAP and BMD. However, DAL based on PRAL was not associated with BMD.

10 December 2023 in BMJ Open
Verified
Journal Article
Open access
PDF file
MNMohammad Naemi
Mohammad Naemi
SNSina Naghshi
Sina Naghshi
SRSomaye Rostami
Somaye Rostami
ESEhsan Safaei
Ehsan Safaei
HTHelda Tutunchi
Helda Tutunchi
AOAlireza Ostadrahimi
Alireza Ostadrahimi
Introduction Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. The efficacy and safety of boron citrate (BC), a novel therapeutic approach, in patients with obesity are not known. The current trial will take place to determine the effects of BC supplementation on cardiometabolic factors, inflammatory biomarkers, anthropometric measures and body composition in obese patients. Methods and analysis This double-blind, placebo-controlled, randomised clinical trial will involve 60 eligible obese participants aged 18–60 years. Participants will randomly be allocated to receive either BC capsules (containing 10 mg of boron) in the intervention group or placebo capsules (containing 10 mg of maltodextrin) in the placebo group for 12 weeks. Moreover, physical activity and dietary recommendations will be provided for both groups. To assess the dietary intakes of participants, a 3-day food record (2 days of the week and 1 day of the weekend) will be filled. Cardiometabolic factors, inflammatory biomarkers including tumour necrosis factor α, C reactive protein, interleukin-6 and interleukin-10 levels, anthropometric measures and body composition will be assessed at the baseline and end of the intervention. The findings of this study will provide evidence for the effectiveness of BC in the management of obesity. Ethics and dissemination There are so far no reported adverse effects associated with the use of boron. This trial was approved by the Ethics Committee of Tabriz University of Medical Sciences (approval number: IR.TBZMED.REC.1401.350). Positive as well as negative findings will be published in peer-reviewed journals. Trial registration number IRCT20220806055624N1.